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Many factors can lead to an inadequate development of piglets during their first days of
life, including poor maternal behavior, which can be due to pain caused by farrowing,
and reduced colostrum ingestion. This study investigates the action of meloxicam
administered orally at farrowing on piglet weight gain and immunity transfer. Thirty-five
multiparous sows were divided into two groups and treated with 0.4 mg/kg of oral
meloxicam (oral meloxicam group; n = 18) or with a mock administration (control group;
n = 17). A total of 382 piglets were individually weighed on the farrowing day (day 0), as
well as on days+9 and+20. Immunoglobulin G (IgG) and A (IgA) concentrations in piglet
serum and in sow’s saliva, colostrum and milk were measured. Additionally, Interleukin-2
(IL-2), Interleukin-4 (IL-4) and Interferon gamma (IFN-g) in serum of piglets and in sow’s
milk or colostrum were studied. All samples were obtained on days +1, +9, and +20.
Piglets from sows in the oral meloxicam group tended to grow faster from day +9 to
day +20 than did piglets from control sows (p = 0.059), and this difference was also
observed in piglets with low body weight (BW) at birth (p = 0.056). The oral meloxicam
group sows tended to increase the colostrum levels of IgA and IgG, as compared with
control sows on day +1 (p = 0.068 and p = 0.072, respectively). IgA levels in piglet
serum from the oral meloxicam group were significantly higher than in the control group
on day +1 and +9 (p = 0.019 and p = 0.011 respectively). Furthermore, IL-2 and IL-
4 levels in the serum of piglets from sows in the oral meloxicam group tended to be
higher than that in the control group on day +9 (p = 0.078 and 0.056, respectively).
The administration of meloxicam orally at the beginning of farrowing in multiparous
sows increased immunoglobin and cytokine concentrations in colostrum, improving both
humoral and cellular immune response of piglets. Pre-weaning growth of piglets born with
a low BW improved in the meloxicam-treated group.
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INTRODUCTION
Piglets are born agammaglobulinemic because of the epitheliochorial placentation of swine (1, 2).
An early and sufficient intake of colostrum is crucial for piglet growth and survival (3, 4), as it
is the source of energy as well as active and passive immunity. Colostrum is a complex mammary
secretion released from the time of farrowing (early-colostrum) to 12 h (mid-colostrum) and up
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to 36 h post-farrowing (late-colostrum) (5). Early-colostrum is
mostly produced before farrowing and contains up to 75% of
Immunoglobulin G (IgG) and 20% of Immunoglobulin A (IgA),
which are central elements of humoral immune responses. After
farrowing, IgG concentration drastically drops, whereas IgA
reduction during lactation is more gradual due to its role in the
regulation of piglet intestinal microbiota, which is critical for the
prevention of digestive problems (5).
Colostrum-associated cellular immunity has been overlooked
for a long time. It contains around 106 cells/mL, up to
25% of them being lymphocytes (6, 7). Immune responses
are orchestrated via complex signaling pathways within cells
mediated by cytokines, which are small proteins with a plethora
of effects. IL-2, IL-4 and IFN-g are important cytokine mediators
of the adaptive immune response, thus their quantification
allows for partial characterization of the immune response.
IL-2 is mainly produced by T lymphocytes and induces the
proliferation of T and B lymphocytes and the activation of
Natural Killer cells (NK) (8–10). IL-4 triggers differentiation
of T helper lymphocytes toward the Th2 subset, which is
related to humoral and anthelmintic responses (8, 10), while
IFN-g activates macrophages and elicits the differentiation of
T helper lymphocytes toward the Th1 subset, thus favoring
cellular responses and boosting protection against intracellular
microbes (10).
Non-steroidal anti-inflammatory drugs (NSAIDs) have
analgesic, anti-inflammatory, anti-endotoxic and anti-pyretic
effects. It has been proven that NSAIDs administered to sows
help them recover from a painful situation such as lameness
(11) or post-partum dysgalactia syndrome (12, 13). NSAIDs also
decrease the mortality rate at weaning in litters from healthy
sows (14) and in sows with dysgalactia syndrome (13). However,
studies on the effect of NSAIDs, on sow welfare, piglet growth
and immunity transfer in healthy sows show discrepancies.
Meloxicam administered to healthy sows around farrowing
improves post-farrowing sow recovery (15, 16) and enhances
piglet growth, especially at weaning (17, 18) and in piglets with
low body weight (BW) at birth (18, 19). Nevertheless, other
studies administering NSAIDs to healthy sows around farrowing
did not find enhanced sow welfare and recovery post-farrowing
(20) or improve piglet growth (15, 21).
To our knowledge, only two studies have looked into the
effects of NSAIDs administered to sows around farrowing
and have assessed passive immunity transfer via colostrum
and immune system development in piglets (18, 20). Both
studies recorded IgG transfer measured in piglet serum without
exploring immunoglobulins in sow colostrum or milk. These
studies did not measure other relevant immune factors for piglet
growth and survival, such as IgA or cytokines. Mainau et al.
(18) demonstrated that the administration of meloxicam orally
at the beginning of farrowing in multiparous sows increased
the concentration of IgG in piglet serum and enhanced their
pre-weaning growth.
The present study aims to evaluate the effect of meloxicam
administered orally to healthy sows at the beginning of farrowing
on piglet growth, also including the effect of sex and immune
transfer via colostrum of immunoglobulins (A and G) and
cytokines (Interleukins IL-2 and IL-4, and Interferon Gamma
IFN-g), taking into account the sow parity effect.
MATERIALS AND METHODS
The experimental protocol described in this experiment was
approved by the Institutional Animal Care and Use Committee
of the Universitat Autònoma de Barcelona (CEEAH-1591) and
the Generalitat de Catalunya (DMAH-6720). Written informed
consent was obtained from the owners for the participation of
their animals in this study.
Animals, Housing and General
Management
Sample size was calculated by means of ENE 3.0. The sow was
the experimental unit. Based on two previous studies carried
out by Mainau et al. (18, 19), a reference mean average daily
gain (ADG) of 0.2 kg/day was established at sow level for the
control group and an expected mean ADG of 0.225 kg/day
was considered for the treatment group. An overall standard
deviation of 0.025 kg/day (at sow level) was assumedwith a power
of 80% and confidence level of 95%. A prevision of 17 sows per
group was predicted.
The experimental procedure was carried out on a commercial
farm (Heura S.L.; Santa Perpètua de Mogoda, Barcelona, Spain),
with 9 farrowing barns equipped with an evaporative cooling
system each. From December 2017 to March 2018, a total of 35
hybrid (Landrace x Duroc) multiparous sows from 2nd to 7th
parturition were randomly selected the day of farrowing. At least
5 replicates with 5 to 10 sows per replicate were studied.
On day 109 of gestation, sows were moved to the farrowing
barn and were housed in individual farrowing crates (1.95 ×
0.60m) built with steel bars. Farrowing crates were centrally
located in farrowing pens (2.40× 1.80m) with fully metal-slatted
floors for sows and plastic-slatted floors for piglets. A metal pad
ensured 36◦C of heat for the piglets during the first week of life,
and heat lamps were placed over the metal pad the first day of
life. The temperature in the farrowing barn was kept constant
at ∼20◦C, and the light was on from 07:00 to 17:00 h every
day. Sows were offered 2.6 kg of feed per day, divided into two
meals (07:00 and 15:00 h) and water was available ad libitum
from drinkers.
Thirty days before farrowing, all sows were vaccinated with
Clostridium novyi (2 mLSuiseng R©, Hipra SA; Girona, Spain).
Sixteen days after farrowing, sows that were not expected to
be culled (n = 31 sows) were vaccinated with Parvovirus and
Erysipelothrix rhusiopathiae (2mL Eryseng R©parvo, Hipra SA;
Girona, Spain) andwith Leptospira spp (2mLAutovacuna R©syva,
Syva SAU; León, Spain). On day 113 of gestation, farrowing was
hormonally induced with 2mL of Planate R© (Cloprostenol 0,092
mg/mL, MSD Animal Health; Friesoythe, Germany) divided into
two injections of 1mL (07:00 h and 11:00 h). Only hormonally
induced farrowings that started on the morning of day 114 of
gestation were included in the study. Lame sows or those with
any kind of visible disease symptoms such as mastitis, diarrhea,
fever, or respiratory problems were not included in the study.
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Treatments and manual interventions during farrowing
followed the usual routine of the farm and were performed
by the same person. The following treatments were allowed
during farrowing and were administered intramuscularly (IM)
in the neck. When the time interval between the birth of
two piglets exceeded 1 h and the cervical canal was dilated,
1mL of Oxytocin (Hormonipra R©, HipraSA, Girona, Spain) was
injected. When the cervical canal was not sufficiently dilated,
sows were treated with 200mg of Vetrabutine hydrochloride
(Monzal R©, Boehringer Ingelheim España; SA, Barcelona, Spain).
When sows were very nervous around farrowing Carazolol
(Suacron R©, Divasa Farmavic SA; Barcelona, Spain) or Azaperone
(Stressnil R©, Janssen Animal Health, Elanco; Brussels, Belgium)
were administered.
A total of 382 piglets, identified individually by a numeric
ear tag, were included in the study. Piglets were weaned at
21 days of age, according to veterinary recommendations, and
moved to another barn of the farm equipped with conditioned
infrastructures for very young piglets.
Experimental Procedure
In each replicate, sows were randomly allocated into two
homogeneous groups, regarding parity, and treated with either
0.4mg/kg bodyweight ofmeloxicam (Metacam R© 15mg/mLOral
Suspension, Boehringer IngelheimVetmedica GmbH; Ingelheim,
Rhein, Germany) or a mock administration with an empty
syringe. Treatments were administered at the beginning of the
farrowing, between the first and the third piglet. If any further
anti-inflammatory treatment was required, the sow was excluded
from the study.
Litter size was standardized at 11–12 piglets by cross-fostering
within 6–8 h post-farrowing. Cross-fostering was carried out
within each treatment. Each treatment was identified with two
different colored cards in order to make the treatment blind to
farm and laboratory staff.
Data Collection
For each sow, the following parameters were registered during
farrowing by direct observations: the duration of farrowing
(defined as the period of time between the first and the last
piglet born), the condition of each piglet at birth (born alive,
stillborn or mummified fetus), the piglet’s sex (male or female),
the number of treatments and manual interventions during
farrowing, and the number of piglets cross-fostered and weaned.
The presence of placenta retention was also recorded. During
lactation, piglet mortality was registered. The number of sows
culled after weaning and the interval between farrowing and the
following fertile insemination were recorded.
One and 9 days after farrowing (day +1 and day +9) and the
day before weaning (day+20), saliva samples were collected from
all sows using Salivette R© tubes (Sarstedt; Nümbrecht, Germany).
Each tube contained a cotton swab, which was clipped with a
Kocher clip, and sows were allowed to chew it for around 1min.
Then, the cotton swab was placed in the tube and centrifuged
at 6,048 × g for 13min. Saliva samples (∼1–2mL per cotton
swab) were stored in Eppendorf tubes and frozen at −80◦C until
analysis. Colostrum and milk samples were collected from all
sows on day +1 (colostrum) and on days +9 and +20 (milk).
Sows were injected with 0.7 mLof Oxytocin IM (Hormonipra R©,
Hipra SA; Girona, Spain), and 30 s later, 2mL of colostrum
and milk were collected into sterile tubes. Colostrum and milk
samples were immediately frozen at−20◦C until analysis.
Each pig was individually weighed at farrowing (day 0), and on
days +9 and +20. One day after farrowing, during one suckling
event, 3–4 piglets of each litter were selected for blood sampling.
Piglets were chosen so that at least one of themwas suckling from
the sow’s craneal teats, another one from middle teats and yet
another one from caudal teats. The same piglets from each litter
were blood sampled on days +1, +9, and +20. Blood samples
(1–2mL) were collected into heparinized tubes from the anterior
vena cava. Samples were centrifuged for 6min at 2,058 × g and
plasma was stored in Eppendorf tubes at−80◦C until analysis.
All samples were analyzed at theMurcia University Veterinary
Hospital Laboratory. Immunoglobulin G (IgG) and A (IgA)
concentrations in piglet serum and sow saliva, colostrum and
milk were quantified by using two commercially available
sandwich ELISAs (IgA and IgG ELISA Quantitation Kit; Bethyl
Laboratories; Montgomery, TX, USA). Interleukin-2 (IL-2),
Interleukin-4 (IL-4) and Interferon gamma (IFN-g) in piglet
serum, sow saliva, milk or colostrum were analyzed using
MILLIPEX R© MAP Porcine Cytokine/Chemokine Panel Kit
(EMDMillipore; Darmstadt, Germany).
Statistical Analysis
Data were analyzed using the SAS software (SAS Institute Inc.;
Cary, NC, USA). The experimental unit for data analysis was the
individual sow. All descriptive values in the Results section are
shown as the mean± standard error (SE). Significance was set at
p < 0.05, and tendency at p < 0.1, in all cases.
The Mann-Whitney Wilcoxon test was used to test whether
the performance values (other than piglet weight and average
daily gain) obtained at the individual sow level were significantly
different between treatments.
Normality tests of residuals were performed for each
dependent variable. Weight of piglets and ADG (From birth to
day+9, from day+9 to weaning and from birth to weaning) were
normally distributed without data transformation. A general
linear mixed model (proc MIXED) for repeated measures was
used. Model included the fixed effects of treatment (control
vs. oral meloxicam), day (at birth, day +9 and at weaning),
sex (males vs. females) and their pair interactions. Day and
piglet within sow were introduced as repeated effects. Weight
at birth was introduced as a covariate for the analysis of weight
at day +9 and at weaning, and litter size was introduced as a
covariate in all the models. The residual maximum likelihood
was used as a method of estimation. Differences in least-square
means were investigated after using a Tukey adjustment for
multiple comparisons. The same models were used to study the
performance of piglets categorized by quintiles according to their
weight at birth: very light (from 0.670 to 1.294Kg), light (from
>1.294 to 1.492Kg), mid (from>1.492 to 1.625Kg), heavy (from
>1.625 to 1.878Kg) and very heavy (from >1.878 to 2.427 Kg).
IgG and IgA concentrations in piglet serum, sow saliva and
colostrum or milk, IL-2, IL-4 and IFN-g in colostrum or milk,
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TABLE 1 | Mean, standard error (SE), median (MED) and 95% confidence intervals for median (95% CI) of performance parameters and treatment records studied in the
control and oral meloxicam groups during the whole trial period (from farrowing to weaning at 21 days).
Control
(n = 17 sows)
Oral meloxicam
(n = 18 sows)
P-value
Items Mean SEa MED 95%CI Mean SE MED 95%CI
Parity 4.06 0.441 3 2–7 4.28 0.394 4 2–7 0.582
Piglets born at the moment of the treatment 1.70 0.143 2 1–3 1.78 0.117 2 1–3 0.856
Total duration of farrowing (h) 3.27 0.328 3.47 1.12–5.47 3.31 0.387 3.06 1.38–7.28 0.817
Total piglets born per litter 13.47 0.912 13 6–21 12.73 0.576 13 9–17 0.621
Live born per litter 11.88 0.624 12 6–18 11.36 0.584 11 8–16 0.489
Stillborn per litter 0.94 0.358 1 0–6 0.83 0.259 0.5 0–4 0.986
Mummified fetus per litter 0.65 0.226 0 0–2 0.55 0.217 0 0–3 0.815
Cross-fostered piglets per litter 11.18 0.231 11 10–13 10.67 0.256 10.5 8–12 0.209
Crushing deaths per litter 0.47 0.229 0 0–3 0.17 0.121 0 0–2 0.322
Total liveborn mortality 0.76 0.304 0 0–4 0.61 0.282 0 0–4 0.662
Total weaned piglets 10.41 0.193 10 9–12 10.06 0.338 10 6–12 0.569
Manual intervention per sow 0.47 0.174 0 0–2 0.38 0.230 0 0–4 0.422
Oxytocin treatment per sow 0.24 0.106 0 0–1 0.17 0.900 0 0–1 0.637
Total treatments per sow 0.24 0.106 0 0–1 0.33 0.140 0 0–2 0.731
A total of 35 sows and 354 piglets were included in the study. P-value from Mann-Whitney Wilcoxon test is shown.
aSE, standard error.
and IFN-g in serum of piglets were normally distributed after
a log transformation. IL-2 and IL-4 in piglet serum followed a
normal distribution without data transformation. Additionally,
extreme outliers detected by proc UNIVARIATE box plot
procedures were deleted.
Immunity measurements in piglets and sows were analyzed
using general linear mixed models (proc MIXED) for repeated
measures. Models for immunity sow measurements included
the fixed effects of treatment (oral meloxicam vs. control), day
(day +1, +9, and +20), parity (from 2nd to 7th) and their pair
interactions. Day was introduced as a repeated effect. Models
for immunity piglet measurements included the fixed effects
of treatment (oral meloxicam vs. control), day (day +1, +9,
and +20), sex (male vs. female), the position at the udder
(anterior, middle and posterior teats) and their pair interactions.
Day and piglet within sow were introduced as repeated effects.
The residual maximum likelihood was used as a method of
estimation. Differences in least-square means were investigated
after using a Tukey adjustment for multiple comparisons. All
general linear mixed models included replicate (from 1 to 5) and
farrowing barn (from 1 to 9) as random effects.
RESULTS
Performance Parameters and Treatment
Records
Results on performance and treatment records at the individual
sow level are summarized in Table 1. Both treatment groups
(oral meloxicam vs. control) were similar when the experimental
procedure started in terms of performance data recorded
during farrowing.
TABLE 2 | Mean and standard error (SE) of the piglet weight at birth, 9 days after
farrowing (day + 9) and at weaning (day + 20) in Kilograms and the Average Daily
Gain (ADG) of piglets from birth to day + 9 after farrowing, from birth to weaning
and from day + 9 to weaning in Kilograms per day for 354 piglets regarding
treatment (control vs. oral meloxicam).
Control Oral meloxicam
Mean SE Mean SE P-value
Weight at birth (Kg) 1.510 0.065 1.600 0.063 0.996
Weight at day +9 (Kg) 3.556 0.071 3.499 6.538 0.909
Weight at weaning (Kg) 6.479 0.109 6.538 0.103 0.644
ADG from birth to day +9 (Kg/day) 0.218 0.010 0.217 0.010 0.981
ADG from birth to weaning (Kg/day) 0.243 0.006 0.251 0.006 0.275
ADG from day +9 to weaning (Kg/day) 0.261b 0.007 0.275a 0.007 0.059
Different superscripts (a, b) in the same row indicate significant differences within each
effect (p < 0.05). Tendency has been shown at p < 0.1.
Treatment did not have an effect on the time interval between
weaning and the following fertile insemination (4.769 ± 0.121
days in oral meloxicam group vs. 7.071 ± 1.811 days in the
control group; p = 0.893), or on the number of sows culled after
weaning (0.111 ± 0.076 in the oral meloxicam group vs. 0.176 ±
0.095 in the control group; p= 0.608).
Twenty-four piglets died during lactation, which represents
6.28% of mortality. Oral meloxicam treatment of sows did not
significantly affect piglet mortality (6.84% from the control group
and 5.73% from oral meloxicam group; p= 0.661).
The mean and standard error (SE) of weight at birth,
weight on day +9 and weight at weaning are summarized in
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Table 2. Piglet weight at birth, on day +9 and at weaning
was not different between the control and the oral meloxicam
group. Piglet sex had a significant effect on the weight of the
piglets, males being heavier than females at weaning (Table 1,
Supplementary Material).
Average daily gain (ADG) data are also summarized in
Table 2. Oral meloxicam treatment of sows tended to increase
piglet ADG from day +9 to weaning. Piglet sex had a significant
effect on the ADG, males growing faster than females from birth
to weaning and from day+9 to weaning.
Piglet weights (at birth, on day +9 and at weaning) and ADG
(from birth to day +9, from day+9 to weaning and from birth
to weaning) were not affected by treatment in piglets born with
light, mid, heavy or very heavy weight at birth. Piglets with very
light weight at birth tended to have a higher ADG from day+9 to
weaning in the oral meloxicam group (267.93± 7.793 gr) than in
the control group (240.11± 9.207 gr) (p= 0.056).
Immunoglobulins G and A Concentrations
in Saliva and Colostrum or Milk of Sows
and in Piglet Serum
Immunoglobulin G andA (IgG and IgA) concentrations in saliva,
colostrum or milk of sows and in piglet serum by treatment effect
on days+1,+9, and+20 after farrowing are shown in Figure 1.
IgG levels in sow saliva (µg/mL) were affected by day after
farrowing (day +1: 44.89 ± 4.486; day +9: 9.08 ± 1.810 and
day +20: 3.28 ± 0.475; p < 0.001 in all pair comparisons), but
were not affected by treatment (p = 0.547) irrespectively of the
day studied.
FIGURE 1 | IgA and IgG at days +1, +9, and +20 after farrowing regarding treatment received by sows (control vs. oral meloxicam) in sow saliva (A,B), sow
colostrum and milk (C,D) and piglet serum (E,F). Significant differences were established at p < 0.01(**) and tendency was set at p < 0.1(#). Boxes represent the
interquartile range (IQ = Q3-Q1), horizontal lines inside the boxes represent the median and the cross (+) represents the mean values of the data. Whisker bars were
calculated from the IQ (Upper: Q3 + 1.5 × IQ; lower: Q1 – 1.5 × IQ), and reflect the variability of the data outside Q1 and Q3. Points outside the box-and-whiskers
plot represent extreme values of the population.
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IgA levels in sow saliva (µg/mL) were affected by day after
farrowing (day +1: 239.64 ± 21.202, day +9: 118.477 ± 12.267
and day +20: 60.81 ± 7.295; p < 0.001 in all pair comparisons),
but were not significantly affected by treatment; (p = 0.704)
irrespective of the day studied.
IgG levels in colostrum or milk of sows (mg/mL) were affected
by day after farrowing and were higher on day +1 (24.48 ±
1.484) than on days +9 (3.75 ± 0.953) and +20 (1.77 ± 0.298)
(p < 0.001 in both cases). IgG levels in colostrum from the
sows treated with oral meloxicam tended to be higher than in
the control group on day +1 (p = 0.072). However, on days
+9 and +20, IgG concentration in sow milk was not affected
by treatment.
IgA levels in colostrum or milk of sows (mg/mL) were affected
by day after farrowing and were higher on day+1 (7.48± 0.577)
than on days+9 (4.41± 0.347; p< 0.001) and+20 (3.72± 0.315;
p < 0.001). IgA concentration on day +9 and +20 were similar
(p= 0.246). Furthermore, IgA levels in colostrum of sows treated
with oral meloxicam tended to be higher than in the control
group on day+1 (p= 0.068), but on day+9 and+20, IgA levels
in sow milk were not affected by treatment.
IgA and IgG concentrations in saliva and in colostrum or milk
were not affected by parity (saliva: p = 0.290 and p = 0.192,
respectively, and colostrum or milk: p = 0.127 and p = 0.232).
The interaction between treatment and parity was not significant
(saliva IgA p = 0.113; IgG p = 0.925 and colostrum or milk IgA
p= 0.239; IgG p= 0.112).
IgG levels in piglet serum (mg/mL) were affected by day after
farrowing (day+1: 29.93± 1.377; day+9: 20.26± 0.935 and day
+20: 11.48± 0.466; p< 0.001 in all pair comparisons). IgG levels
in piglet serum were not significantly affected by treatment (p =
0.963), sex (p= 0.189) or piglet position at the udder (p= 0.811)
irrespective of the day studied.
IgA levels in piglet serum (mg/mL) were affected by day after
farrowing (day +1: 20.63 ± 1.314, day +9: 1.36 ± 0.080 and
day +20: 0.27 ± 0.018 p < 0.001 in all pair comparisons), and
there was an interaction between treatment and sampling day
(p = 0.020). IgA levels in piglet serum from sows treated with
oral meloxicam were significantly higher than in piglets from
the control group on day +1 (p = 0.019) and day +9 (p =
0.011). However, on day +20, IgA level in piglet serum was not
significantly affected by treatment (p= 0.943). IgA levels in piglet
serum were not significantly affected by sex (7.79 ± 0.944 in
females vs. 7.89± 1.001 in males; p= 0.633) or by piglet position
at the udder (anterior teats: 7.67 ± 1.048, middle teats: 7.17 ±
1.328 and posterior teats: 9.07± 1.448, p= 0.725) irrespective of
the day studied.
Concentration of Cytokines (IL-2, IL-4 and
IFN-g) in Colostrum or Milk of Sows and in
Piglet Serum
Concentration of interleukins (IL-2 and IL-4) and interferon
gamma (IFN-g) in colostrum ormilk of sows and in piglet serum
by treatment effect on days +1, +9, and +20 after farrowing are
shown in Figure 2.
IL-2, IL-4 and IFN-g concentration in colostrum or milk of
sows (ng/mL) were affected by day after farrowing (p < 0.001
in all cases). IL-2, IL-4 and IFN-g in sow colostrum on day +1
(IL-2: 1.51 ± 0.166; IL-4: 10.12 ± 1.289; IFN-g: 62.99 ± 5.505)
showed higher concentrations than in sow milk on day+9 (IL-2:
0.50 ± 0.079; IL-4: 2.60 ± 0.540; IFN-g: 24.31 ± 3.827) and on
day +20 (IL-2: 0.73 ± 0.089; IL-4: 4.02 ± 0.641; IFN-g: 41.86 ±
4.585), whereas concentrations on day +20 were higher than on
day+9.
IL-2, IL-4, and IFN-g concentrations in colostrum or milk
of sows were not significantly affected by treatment (p = 0.206,
0.142, and 0.322 respectively).
IL-2, IL-4 and IFN-g concentrations in colostrum or milk of
sows were affected by parity (p = 0.010, p < 0.001 and p = 0.008
respectively). The general pattern was that sows in their second
parity showed lower levels of cytokines than did older sows (three
parturitions or more). Specifically, IL-2 levels in colostrum or
milk of sows in their second parity were lower than those in sows
in their fourth (p= 0.016) and fifth parity (p= 0.023) and tended
to be lower than in sows in their seventh parity (p = 0.098). IL-4
levels in colostrum or milk of sows in their second parity were
lower than those in sows in their third (p = 0.005), fourth (p
= 0.001), fifth (p = 0.001), sixth (p = 0.035) and seventh parity
(p = 0.002). IFN-g levels in colostrum or milk of sows in their
second parity were lower than those in sows in their fourth parity
(p = 0.008) and tended to be lower than in sows in their sixth
parity (p= 0.070).
IL-2 and IL-4 levels in piglet serum (ng/mL) were affected by
day after farrowing, and were higher on day +9 (IL-2: 2.40 ±
0.173; IL-4: 17.15 ± 1.442) than those on days +1 (IL-2: 1.33
± 0.070; IL-4: 8.53 ± 0.526; p < 0.001 in both cases) and +20
(IL-2: 1.55 ± 0.145; IL-4: 10.67 ± 1.156; p < 0.001 and p =
0.001, respectively).
IL-2 and IL-4 levels in piglet serumwere affected by treatment,
and tended to be higher in the oral meloxicam group than
those in the control group on day +9 (p = 0.078 and p =
0.056, respectively). IL-2 and IL-4 levels in piglet serum were not
significantly affected by sex of piglets (p = 0.596 and p = 0.868,
respectively) or by piglet position at the udder (p = 0.888 and p
= 0.715, respectively) irrespective of the day studied.
IFN-g levels in piglet serum (ng/mL) were affected by day
after farrowing, and were lower on day +1 (6.00 ± 0.334) than
those on day+9 (10.74± 0.654) and day+20 (12.07± 0.758) (p
< 0.001 in all cases).
IFN-g levels in piglet serum were not significantly affected by
treatment (p= 0.409), sex of piglets (p= 0.858), or piglet position
at the udder (p= 0.320), irrespective of the day studied.
DISCUSSION
In the present study, both treatment groups (oral meloxicam
and control) were well-matched in terms of performance
variables recorded during farrowing. Early administration of
oral meloxicam treatment did not negatively affect total piglets
born alive per litter, total duration of farrowing, treatments
administered during farrowing (such as oxytocin) or the number
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FIGURE 2 | Concentration of IL-4, IL-2, and IFN-g at days +1, +9, and +20 after farrowing regarding treatment received by sows (control vs. oral meloxicam) in sow
colostrum and milk (a, c, e) and piglet serum (b, d, f). Tendency differences were established at p < 0.1(#). Boxes represent the interquartile range (IQ = Q3 – Q1),
horizontal lines inside the boxes represent the median and the cross (+) represents the mean values of the data. Whisker bars were calculated from the IQ (Upper: Q3
+ 1.5 × IQ; lower: Q1 - 1.5 × IQ) and reflect the variability of the data outside Q1 and Q3. Points outside the box-and-whiskers plot represent extreme values of the
population.
of manual interventions during farrowing. Hence, it appears that
the use of oral meloxicam during parturition (more specifically
between the first and the third piglet born) did not interfere with
the progression of the birth process.
Piglet Mortality and Growth
In agreement with other authors that studied the effect of
NSAIDs around farrowing (17, 18, 20, 21), oral meloxicam
administered to healthy sows did not show an effect on pre-
weaning piglet mortality. On the contrary, Homedes et al. (14),
in a large-scale study on commercial farms with a high incidence
of pre-weaning mortality (±10%), showed lower pre-weaning
piglet mortality after ketoprofen administration to sows within
12 h after farrowing. Homedes et al. (14) explained such an
effect due to higher milk production by the sow ketoprofen-
treatment group. We assume that a larger sample size enrolling
different farms with high pre-weaningmortality would be needed
to observe differences in piglet mortality (piglet mortality in our
study was 6.8%).
Piglet weights at birth were similar (16, 17) or slightly
higher (3, 22, 23) than values reported in other studies. The
administration of oral meloxicam at the beginning of farrowing
tended to enhance the ADG of piglets from day +9 to weaning,
and particularly for the lightest piglets. A similar effect was
described by Mainau et al., in two studies (18, 19), treating
the sows around farrowing with injectable and with oral
meloxicam. Tenbergen et al. (17), injected meloxicam intra-
muscularly within 12 h of farrowing and found that piglet ADG
tended to be higher for piglets from the meloxicam group
sows than for control piglets in medium-sized litters (11–13
piglets). Ketoprofen is another AINE used in pig production,
but Viitasaari et al. (21) and Ison et al. (15), who both injected
sows with ketoprofen during farrowing, did not find that it
had any effect on piglet average daily gain to weaning. These
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discrepancies in the effects of NSAIDs administered to healthy
sows around farrowing on piglet growth could be due to different
factors such as the active principle administered. Meloxicam is a
selective COX-2 inhibitor and may be a more specific treatment
for inflammation caused by farrowing than a non-selective COX
inhibitor, like ketoprofen (24). The time of administration is
another important factor to take into consideration. Studies
administering meloxicam at the beginning of farrowing (17–19)
show the effect on weaning weights of piglets and ADG. Thus,
the active ingredient administered (preferably a selective COX-2
inhibitor) and the administration time (as soon as possible after
farrowing starts) are presumably important factors to improve
piglet growth and weight at weaning.
Transfer of Passive and Active Immunity
Colostrum intake is crucial for development of piglet immunity.
In this study, and in accordance with normal colostrum and
milk immunoglobulin kinetics (5), sow colostrum and milk
IgG and IgA showed an abrupt and steady decrease respectively
(Figures 1C,D). Interestingly, colostrum immunoglobulin
content on day +1 was higher in the oral meloxicam group then
in the control group. The difference between groups was more
pronounced in IgA than in IgG, which could be explained by
the switch between the IgG/IgA ratio after farrowing (5). One-
hundred percent of colostrum IgG and 40% of colostrum IgA
come from sow blood via an Ig receptor, whereas up to 60% of
IgA is directly synthesized in the mammary gland (1). Our data
support the local role of oral meloxicam in the mammary gland,
which likely decreases local inflammation, thus favoring both
immunoglobulin recruitment from plasma and local production
of IgA in plasma cells (1). Indeed, in vitro studies developed in
cattle have shown the anti-inflammatory effect of meloxicam in
mammary epithelial cells (25). Furthermore, mastitis in cows has
been associated with reduced pre-weaning immunity, growth,
and health of the offspring (26, 27), so the anti-inflammatory
effect elicited by meloxicam treatment is presumed to have the
opposite effect.
In comparison with blood sampling, saliva sampling is
generally considered to be a non-invasive and stress-free
methodology (28). IgG levels in sow saliva are directly
proportional to the levels in sow serum, whereas IgA in saliva
is mostly produced locally, so IgA levels are highly variable
in response to environmental factors such as stress and oral
infections (29). In our study, saliva IgG levels, a marker of
plasma IgG levels, showed no differences between groups,
which probably rules out a systemic effect of oral meloxicam
administration on the Ig increase in piglets from treated sows.
IgA and IgG concentration in piglet serum during lactation
is the result of intake of immunoglobulins from colostrum.
The quick drop of IgA and the slow drop of IgG in piglet
serum is likely explained by the different half-lives of these
immunoglobulins in serum, being 6 days for IgA and 21 days
for IgG (30). IgA concentration was higher in piglet serum in
the oral meloxicam group on days +1 and +9. Interestingly,
diarrhea of newborn piglets is one of the biggest health issues
in pig production, and increased IgA levels could play a major
role in preventing these problems by their protective effect
on the intestinal mucosa (1). Mainau et al. (18) found that
the administration of meloxicam orally at the beginning of
farrowing (on average, when 2.6 piglets had already been born)
increased the concentration of IgG in the serum of piglets. In
the present study, sows were treated early at the beginning
of farrowing, when early colostrum (with the highest IgG
levels) has already been produced and thus the influence of
treatment on the IgG serum levels of piglets fed with this
colostrumwas lower. Nevertheless, weaker piglets and those born
later during parturition are known to suffer from delayed and
reduced colostrum intake (31). These animals have lower survival
and growth rates, which may be improved by treatment with
meloxicam, as shown by our results with piglets born with a
very light weight at birth, as well as by other studies (31). These
differences could be explained by a higher IgG and IgA immunity
transfer in the treatment group in these weaker animals, which
are likely to consume a smaller quantity of early-colostrum and a
larger proportion of mid- and late-colostrum. Unfortunately, in
this study a low percentage of piglets with low BW at birth were
blood sampled, thus hampering a proper analysis of their serum
IgG and IgA levels.
Regarding colostrum and milk cytokines, higher levels of IL-
2, IL-4, and IFN-Y were found on day +1, which is likely to
be related to pain and to contamination of the reproductive
tract induced by farrowing. Milk cytokine levels moderately
decreased between day +1 and +9 and increased again between
day +9 and +20, likely in response to the vaccination given
to sows on day +16. Cytokines and lymphoid cells have been
demonstrated to cross the intestinal barrier of newborn piglets
(32–34). In piglet serum, cytokine levels measured on day +1
are expected to be the result of both colostrum-derived cytokines
and cytokines produced by the piglets. In contrast, taking into
consideration the short half-life of these cytokines (minutes
for IL-2 and IL-4 and a few hours for IFN-g) and the loss
of piglet intestinal permeability, cytokine levels on days +9
and +20 reflect only the activity of the piglet immune system.
Higher concentrations of all cytokines were found on day +9,
likely due to the immune challenge elicited by tail docking (in
both sexes) and castration (in males), which were performed
on their second day of life. Interestingly, higher IL-4 and IL-
2 levels were measured in piglets from the meloxicam treated
group on days day +9 (Figures 2B,D). Increased secretion of
IL-4 and IL-2 in piglets has been related to better Th2 and
Th1 immune responses, respectively (8). Moreover, IL-4 induces
antibody production and tissue repair, whereas IL-2 plays a
major role in the activation of NK-cells and the generation
of effector and memory cells (9, 10). This positive influence
of colostrum on the immune system development could be
related to the transfer of colostrum-associated immune cells,
which are absorbed selectively in the newborn gut, although the
precise mechanisms remain unclear (1). Therefore, it could be
hypothesized that meloxicam treatment around farrowing had an
impact on the concentration of immune cells in colostrum, but
further studies are needed to investigate this hypothesis.
This study was developed on a commercial farm with
really good sanitary and husbandry conditions. Further
research is required to determine if these positive results on
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piglet welfare can be even more pronounced by studing a
larger set of commercial farms with higher mortality rates
and lower growth rates during lactation. In summary, the
results of this study show that early administration of oral
meloxicam improves some aspects of piglet performance
and welfare. Further research is needed to study whether
these effects are also observed in primiparous sows or could
be improved by administering meloxicam before the onset
of farrowing.
CONCLUSIONS
The administration of meloxicam orally at the beginning of
farrowing in multiparous sows increased the concentration of
immunoglobins and cytokines in sow colostrum and improved
both humoral and cellular immune response in piglets. Pre-
weaning growth of piglets, especially in piglets born with low BW,
tended to be higher in the meloxicam-treated group than that in
the control group.
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